Objectives: Mycobacterial persistence is thought to be the underlying cause of the current lengthy tuberculosis therapy and latent infection. Despite some recent progress, the mechanisms of bacterial persistence are poorly understood. We have recently identified a new persister gene phoU from Escherichia coli and have shown that the phoU mutant has a defect in persisters. The objective of this study is to evaluate the role of two phoU homologues phoY1 and phoY2 from Mycobacterium tuberculosis in mycobacterial persistence.
Introduction
Tuberculosis (TB) is a leading infectious killer worldwide despite chemotherapy and BCG vaccine. The causative agent Mycobacterium tuberculosis is a highly successful pathogen, which has latently infected one-third of the world population and causes 9 million new TB cases and 1.6 million deaths worldwide each year.
1 This global TB situation is expected to be exacerbated by the spread of HIV infection and increasing emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).
2 -4 Although the current TB therapy can cure the disease, it is too long and takes at least 6 months. The lengthy TB therapy makes patient compliance difficult and frequently causes selection of drug-resistant strains. The lengthy TB therapy is thought to be due to the presence of mycobacterial persisters that are not effectively killed by the current TB drugs. 5, 6 Due to the problem of drug-resistant and persister TB, there is currently a great deal of interest in understanding the persister mechanisms and developing new drugs that target persisters to shorten TB therapy. 6, 7 Persisters were first described by Hobby et al. 8 in 1942 when they found that penicillin killed 99% of a streptococcal culture leaving 1% of the bacterial population intact. This phenomenon was more carefully defined by Bigger in 1944 when he coined the term 'persisters' for the 1% surviving bacteria not killed by penicillin. 9 Although persisters were initially defined using log phase cultures that contain a small number of non-growing persisters, the definition of persisters has subsequently been extended to also include non-growing persisters that are enriched in stationary phase cultures. 10, 11 Thus, antibiotic-tolerant bacteria that are not killed by antibiotics but can regrow in the absence of antibiotics and remain susceptible to the same antibiotics are called persisters. Persisters are characterized by slow or no growth with low metabolic activity and phenotypic resistance to antibiotics. 10 The presence of the persister phenomenon has been documented in numerous bacterial species including M. tuberculosis. 5, 6, 11 Persisters in biofilms and many bacterial infections pose a significant challenge for treatment and disease control. 5, 11 Despite the original observation of the persistence phenomenon 60 years ago, the mechanisms of persister formation are poorly understood. Recent studies suggest that toxin -antitoxin (TA) modules may be involved in persister formation. 11 The first TA module linked to persistence in Escherichia coli is HipBA. 12 HipB and HipA, like other TA modules such as RelBE and MazEF, are organized in an operon with the gene hipB encoding the antitoxin, located upstream of the toxin gene hipA. 13 Overexpression of wild-type toxin such as HipA or RelE caused 10-to 1000-fold more persisters. 14, 15 HipA and RelE could inhibit macromolecule (protein, RNA and DNA) synthesis and slow down or even stop cell division, raising the possibility that toxins of the TA modules may be involved in persister formation. 11 However, deletion of TA modules such as hipA did not cause a defect in persistence 15, 16 presumably due to their redundancy in the genome. A recent study showed that overexpression of unrelated toxic proteins, such as heat shock protein DnaJ and protein PmrC, also caused higher persister formation. 17 This finding questions the significance of TA modules as a specific and universal mechanism for persister formation.
In M. tuberculosis, isocitrate lyase (ICL), required for fatty acid catabolism, was found to be involved in mycobacterial persistence. 18 In addition, inactivation of RelA led to a defect in persistence in the mouse model. 19 We have recently identified a new persister gene phoU, involved in persister formation in E. coli.
16
PhoU is a negative regulator of the pst operon involved in phosphate uptake but its function is not known. We recently showed that inactivation of phoU in E. coli leads to a dramatic defect in persister phenotype as demonstrated by reduced persister numbers in persister assays and increased susceptibility to a diverse range of antibiotics and stress conditions (acid pH, starvation, etc.), especially in stationary phase or starved cultures compared with log phase cultures. 16 Microarray studies indicated that the E. coli phoU mutant surprisingly expressed high levels of genes involved in energy production and metabolism, efflux/ transport, and flagella and chemotaxis synthesis, suggesting that PhoU is a global repressor for cellular metabolism and its inactivation leads to a hyperactive metabolic state as the underlying cause of the persistence defect. This study provides the first evidence of PhoU being a master regulator, beyond its role in phosphate metabolism, being involved in persister formation. We thus proposed a model based on PhoU that serves as a general repressor of cellular metabolism to suppress cellular metabolic activity to facilitate persister formation. 16 PhoU is a ubiquitous protein present in virtually all bacterial species, including M. tuberculosis.
M. tuberculosis, which is notorious for its ability to persist in vivo despite antibiotic treatment, has two PhoU homologues, PhoY1 and PhoY2, 16 which share 63.4% amino acid identity to each other. PhoY1 and PhoY2 have, respectively, 40% and 44% homology to E. coli PhoU. The role of PhoY1 and PhoY2 in the persistence of M. tuberculosis is unclear. In this study, we constructed mutants of PhoU homologues phoY1 and phoY2 and evaluated the role of PhoY1 and PhoY2 in the persistence of M. tuberculosis. We show that M. tuberculosis phoY2 is the equivalent of E. coli phoU and that inactivation of phoY2 but not phoY1 caused a defect in the persistence phenotype including increased susceptibility to antibiotics and decreased persister formation in vitro, and also reduced persistence in the mouse model, a phenotype that can be complemented by the functional wild-type phoY2 gene.
Materials and methods

Bacterial growth conditions
Bacterial strains and plasmids used are shown in Table 1 . E. coli strains were grown in Luria-Bertani (LB) broth or on LB broth agar. Mycobacterium smegmatis mc 2 155 was grown in LB broth containing 0.5% glycerol, 0.5% dextrose and 0.05% Tween 80. M. tuberculosis strain H37Rv was grown in 7H9 liquid medium (Difco) supplemented with 0.05% Tween 80 with 10% bovine serum albumin-dextrose-catalase (ADC) enrichment (Difco) at 378C for 2-3 weeks with occasional agitation. When required, the following antibiotics were used at the specified concentrations: kanamycin (25 mg/L) and hygromycin B (150 mg/L for E. coli and 50 mg/L for M. tuberculosis).
Knockout mutant construction and complementation
phoY1 and phoY2 genes of M. tuberculosis H37Rv were disrupted using specialized transduction as described previously. 20 To create phoY1::hyg and phoY2::hyg, the hygromycin resistance cassette was used to replace the respective gene's open reading frames. Successful deletion of the gene was confirmed by junction PCR and DNA sequencing. For complementation of the deletion mutants, wild-type phoY1 and phoY2 genes were amplified from H37Rv genomic DNA by PCR and cloned into mycobacterial shuttle vector pMV261 followed by electroporation into the mutants as described previously. 21 Primers used to construct phoY1 and phoY2 mutants and complementation are shown in Table 1 .
MIC/MBC determination and drug exposure assays
The MICs of isoniazid and rifampicin were determined by using serial 2-fold dilutions of the compound in 7H9 medium and on 7H11 agar. The MIC of pyrazinamide was determined in 7H9 medium or on 7H11 agar at pH 5.6. The initial cell density was 10 5 cfu/mL of log phase culture, and the samples were incubated for 15 days at 378C. The MIC was recorded as the minimum drug concentration that prevented visible growth, and the MBC was recorded as the drug concentration that reduced cfu by 100-fold over the seeded inoculum in the MIC testing.
For drug exposure persister assays, the survival of stationary phase cultures of the phoY1 and phoY2 mutants and the wild-type H37Rv to pyrazinamide (200 mg/L) and rifampicin (8 mg/L) was determined. Drug exposure with pyrazinamide was performed in acidic medium pH 5.5 as described previously. 22 The drug exposure was carried out over a period of 3 -9 days at 378C without shaking. Aliquots of bacterial cultures exposed to the drug were taken at different timepoints and washed in PBS buffer before plating on 7H11 agar plates for cfu count.
Survival and persistence of DphoY1 and DphoY2 mutants in the mouse model
Six-week-old female BALB/c mice (NCI, Frederick, MD, USA) were infected via the tail vein with M. tuberculosis strain H37Rv, DphoY1 mutant, DphoY2 mutant and the respective mutant complemented strains (all at 1×10 4 cfu) in 100 mL of PBS/0.05% Tween 80 using a low dose latent infection model as described previously. 23 Mice (five mice per group) infected with the above different mycobacterial strains were housed in a BSL-3 animal facility. After 8 weeks of infection, mice were sacrificed and the infected organs (lungs and spleens) were homogenized in PBS/0.05% Tween 80, and the homogenates and their appropriate dilutions were plated on 7H11 plates containing 10% ADC and the antibiotic cocktail PANTA (Becton Dickinson, Sparks, MDk, USA) to prevent contamination. Plates were incubated at 378C in a 5% CO 2 environment for 4 weeks before cfu counts were determined. The Johns Hopkins University Animal Care and Use Committee approved all animal procedures.
Statistical treatment
Pairwise comparison of the cfu data for statistical significance was performed using Student's t-test.
Results and discussion
Construction of DphoY1 and DphoY2 mutants of M. tuberculosis H37Rv
To determine the effect of mutation of phoY1 and phoY2 on the persistence phenotype of M. tuberculosis, we first constructed knockout mutant DphoY1::hyg and DphoY2::hyg alleles using specialized transduction with the temperature-sensitive phage phAE159 as described in the Materials and methods section. Hygromycin-resistant colonies were obtained, which were suggestive of a double-crossover gene replacement event. Junction PCR was used to confirm the mutant genotype for the mutant alleles with the wild-type strain H37Rv as a control. The 666 bp (phoY1) and 642 bp (phoY2) fragments were observed in the wild-type but not in the phoY1 and phoY2 knockout mutants, indicating successful construction of DphoY1 and DphoY2 mutants of M. tuberculosis.
Inactivation of M. tuberculosis PhoU homologue PhoY2 but not PhoY1 caused increased susceptibility to TB drugs
Since the E. coli phoU mutant has a defect in persister formation as demonstrated by increased susceptibility to antibiotics and a reduced number of persisters, 16 we subjected the phoY1 and phoY2 mutants to antibiotic susceptibility tests and also persister assays as described in the Materials and methods section. Interestingly, inactivation of phoY2 caused increased susceptibility to TB drugs rifampicin and pyrazinamide compared with the wildtype H37Rv in both MIC and MBC experiments (see Table 2 ). Specifically, the MICs of rifampicin and pyrazinamide for the phoY2 mutant decreased 4-fold and 2-fold, respectively, in 7H9 liquid medium. The MBC of rifampicin for the phoY2 mutant was 4-fold less than that for the parent strain H37Rv but the MBC of pyrazinamide remained unchanged (Table 2) . However, inactivation of phoY1 did not significantly alter susceptibility to rifampicin or pyrazinamide in MIC or MBC experiments. 
PhoU homologue PhoY2 involved in TB persistence
Decreased persisters in PhoY2 mutant and not PhoY1 mutant upon pyrazinamide and rifampicin exposure
To determine the effect of pyrazinamide and rifampicin on the persister survival of the phoY1 and phoY2 mutants, we subjected stationary phase cultures of the parent strain H37Rv and the above mutants to pyrazinamide (200 mg/L) at pH 5.6 and rifampicin (8 mg/L) at pH 7.0, and determined the cfu values at 0, 3, 9 and 17 days after exposure. No significant difference in survival between the phoY1 and phoY2 mutants and the parent strain H37Rv was observed after 3 days exposure to either pyrazinamide or rifampicin (P.0.05). After 9 days pyrazinamide or rifampicin exposure, there was no difference in survival between phoY1 mutant and the parent strain H37Rv, but the survival of the phoY2 mutant was greatly decreased and no persisters were detectable (detection limit 100 bacteria) (Table 3) . However, at day 17, all viable bacteria were killed by pyrazinamide for both the mutants and the parent control strain H37Rv so a comparison to show the defect in persisters of the phoY2 mutant was not possible (data not shown). In the drug-free control, there was no significant decrease in cfu values for the phoY2 and phoY1 mutants or the control strain H37Rv, indicating that the loss of persisters after rifampicin or pyrazinamide exposure for the phoY2 mutant is specific for the defect in phoY2 and not due to non-specific cell death during the nutrient-limiting conditions during exposure to the drug. These results suggest that PhoY2, but not PhoY1, is the equivalent of E. coli PhoU in M. tuberculosis. It is of interest to note that the defect in persister survival of phoY2 was not obvious at the earlier timepoint of 3 day drug exposure but was seen only after extended exposure up to 9 days. This is consistent with our previous findings for the E. coli phoU mutant, which, in the drug exposure persister assay, also require a relatively long time for the persistence defect to be demonstrated. 16 Future studies are needed to determine whether the PhoY2 mutant also has defective persistence to other TB drugs such as fluoroquinolones and aminoglycosides.
PhoY2 mutant has a defect in persistence in the mouse model of TB infection
To further verify the persister-defective phenotype of the M. tuberculosis phoY2 mutant as shown above, we evaluated the persistence of the phoY2 and phoY1 mutants and their respective complemented strains along with the parent control strain H37Rv using a low dose latent TB infection mouse model as described in the Materials and methods section. Mice were infected with comparably low numbers of the above mycobacterial strains ( 10 4 bacilli) as described in the Materials and methods section. The survival of various mycobacterial strains was determined after 8 weeks of infection. As can be seen in Table 4 , the PhoY2 mutant was less able to survive and persist in the mouse lungs and spleens as shown by an 10-to 30-fold decrease in cfu counts compared with the virulent (Table 4 ). This experiment validates that the PhoY2 mutant not only has an in vitro defect in persister survival in drug exposure assays as shown above, but also exhibited an in vivo persistence defect in the mouse model (Table 4) . Our data suggest that PhoY2 mutation does alter persistence as shown by the persister drug exposure assay, the mouse study and also the MIC/MBC values for the PhoY2 mutant. There is significant debate regarding whether persister mutants have any alteration in MIC/MBC values. It has been proposed that persister mutants should not alter the MIC but only affect persistence. 24 However, this may not necessarily be true as mutation in persister genes could well affect antibiotic susceptibility not only in persisters as shown in persister assays but also in growing bacteria as shown in MIC/MBC tests in the case of PhoU mutation 16 and also SucB and UbiF mutations. 25 In addition, we have found that mutants with a defect in persistence may or may not have altered MIC/MBC values (J. Chen and Y. Zhang, unpublished data).
It has been demonstrated that PhoU expression is correlated with persister formation as it is only expressed in stationary phase or aged cultures under nutrient-limiting conditions 16, 26 or overexpressed in biofilms of E. coli. 27 In our PhoU overexpression study using arabinose-inducible pBAD vector, we found that overexpression of phoU caused increased persister formation in log phase E. coli cultures, but overexpression of control genes ruvA, fur and rcsB involved in L-form formation 28 in the same vector did not (W. Shi and Y. Zhang, unpublished observation). Studies are underway to assess whether controlled overexpression of phoY2 also leads to increased persister formation in M. tuberculosis. More recently, consistent with our previous finding that PhoU is important for persister formation in E. coli, 16 Lee et al. 29 found that PhoU played a critical role in persister phenotype in Pseudomonas putida as shown by higher susceptibility and decreased persisters in the phoU mutant. It is of interest to note that phoY2 (Rv0821c) was significantly up-regulated in a 96 h nutrient starvation persistence model of M. tuberculosis, 30 suggesting that phoY2 may be important for mycobacterial persistence. Our findings in this study provide further evidence that phoY2 is involved in persistence in M. tuberculosis. Future studies are needed to determine the persister phenotype to other TB drugs such as aminoglycosides and quinolones, long-term persistence of the phoY2 mutant in the mouse model and also to elucidate the mechanism by which phoY2 mediates persistence in M. tuberculosis.
In conclusion, we have shown that the M. tuberculosis PhoU homologue PhoY2 but not PhoY1 is the equivalent of E. coli PhoU as demonstrated by increased susceptibility to TB drugs and a defect in persistence in the mouse model. This is another study that confirms the role of PhoU in persistence in a different organism (i.e. M. tuberculosis) besides E. coli. Studies are currently underway to address the detailed mechanisms of how PhoU or PhoY2 mediates persister formation. The identification of PhoY2 as being involved in mycobacterial persistence is a significant finding that has implications on not only understanding the mechanism of persistence but also development of new drugs and vaccines that target persister organisms for improved control of TB.
